JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Dexamethasone
Drug: Lenalidomide

First Posted Date: 2014-03-03

Last Posted Date: 2024-11-05

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 569

Registration Number: NCT02076009

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Canagliflozin, 300 mg
Drug: CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg
Drug: CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg
Drug: Metformin XR, 500 mg

First Posted Date: 2014-02-27

Last Posted Date: 2014-09-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 52

Registration Number: NCT02073227

A Study to Examine the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of TMC435 in Healthy Chinese Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: TMC435 150 mg
Drug: TMC435 100 mg

First Posted Date: 2014-02-25

Last Posted Date: 2014-09-30

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 32

Registration Number: NCT02071355

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Canagliflozin, 300 mg
Drug: CANA/MET XR FDC, Formulation 1, 150 mg/500
Drug: CANA/MET XR FDC, Formulation 2, 150 mg/500 mg
Drug: Metformin XR, 500 mg

First Posted Date: 2014-02-25

Last Posted Date: 2014-07-01

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 3

Registration Number: NCT02071368

A Study to Investigate the Effect of JNJ-42847922 on Polysomnography Measures in Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants

Phase 1

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: JNJ-42847922
Other: Placebo

First Posted Date: 2014-02-20

Last Posted Date: 2016-02-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 20

Registration Number: NCT02067299

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Phase 3

Completed

Conditions: Diabetic Nephropathy
Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Canagliflozin

First Posted Date: 2014-02-19

Last Posted Date: 2019-12-05

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 4401

Registration Number: NCT02065791

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Canagliflozin, 100 mg
Drug: CANA/MET XR FDC, Formulation 1, 50 mg/500 mg
Drug: CANA/MET XR FDC, Formulation 2, 50 mg/500 mg
Drug: Metformin XR, 500 mg

First Posted Date: 2014-02-19

Last Posted Date: 2014-06-17

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 2

Registration Number: NCT02065752

A Study to Evaluate the Pharmacokinetics of Intranasal Esketamine Administered With and Without a Nasal Guide on the Intranasal Device

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Esketamine

First Posted Date: 2014-02-12

Last Posted Date: 2014-03-13

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 14

Registration Number: NCT02060929

A Study to Assess the Effect of Food on the Bioavailability of Mebendazole From a Fast-Disintegrating Chewable Formulation of Mebendazole in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Mebendazole - fasted state (Treatment A)
Drug: Mebendazole - fed state (Treatment B)

First Posted Date: 2014-01-31

Last Posted Date: 2014-06-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 1

Registration Number: NCT02051738

Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CANA/MET XR FDC

First Posted Date: 2014-01-17

Last Posted Date: 2014-04-02

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 12

Registration Number: NCT02039245

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy